An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

Mark D. Danese, Robert I. Griffiths, Michelle Gleeson, Sacha Satram-Hoang, Kevin Knopf, Joseph R Mikhael, Carolina Reyes

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and to evaluate outcomes in those patients who initiated infused therapy. Patients 66 years of age and older in the Surveillance, Epidemiology, and End Results (SEER) program with a CLL diagnosis were matched to their Medicare Part A and Part B claims for long-term follow-up. Treatment patterns, survival after initiation of infused therapy, and both hematologic and hospitalization outcomes were assessed. There were 6433 CLL patients identified, and 2040 received infused therapy. Treated patients were categorized as receiving rituximab monotherapy (16%), rituximab plus chemotherapy (14%), and chemotherapy alone (70%) based on the initial 60 days after infusion. Rituximab plus chemotherapy compared with chemotherapy alone was associated with a 25% lower risk of overall mortality (95% confidence interval, 9%-38%). Restricting to patients age 70 years and older did not change the risk reduction for rituximab plus chemotherapy. Hematologic interventions were more common with rituximab plus chemotherapy compared with chemotherapy alone, but there was no difference in all-cause hospitalizations. These analyses, based on observational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group of older CLL patients are comparable with those demonstrated in younger patients.

Original languageEnglish (US)
Pages (from-to)3505-3513
Number of pages9
JournalBlood
Volume117
Issue number13
DOIs
StatePublished - Mar 31 2011

Fingerprint

Chemotherapy
B-Cell Chronic Lymphocytic Leukemia
Medicare
Observational Studies
Drug Therapy
Therapeutics
Medicare Part A
Hospitalization
Epidemiology
SEER Program
Risk Reduction Behavior
Rituximab
Confidence Intervals
Survival
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Danese, M. D., Griffiths, R. I., Gleeson, M., Satram-Hoang, S., Knopf, K., Mikhael, J. R., & Reyes, C. (2011). An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood, 117(13), 3505-3513. https://doi.org/10.1182/blood-2010-08-301929

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. / Danese, Mark D.; Griffiths, Robert I.; Gleeson, Michelle; Satram-Hoang, Sacha; Knopf, Kevin; Mikhael, Joseph R; Reyes, Carolina.

In: Blood, Vol. 117, No. 13, 31.03.2011, p. 3505-3513.

Research output: Contribution to journalArticle

Danese, MD, Griffiths, RI, Gleeson, M, Satram-Hoang, S, Knopf, K, Mikhael, JR & Reyes, C 2011, 'An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia', Blood, vol. 117, no. 13, pp. 3505-3513. https://doi.org/10.1182/blood-2010-08-301929
Danese, Mark D. ; Griffiths, Robert I. ; Gleeson, Michelle ; Satram-Hoang, Sacha ; Knopf, Kevin ; Mikhael, Joseph R ; Reyes, Carolina. / An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. In: Blood. 2011 ; Vol. 117, No. 13. pp. 3505-3513.
@article{a9c55a5f7e284c768dd7e168f33114ce,
title = "An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia",
abstract = "The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and to evaluate outcomes in those patients who initiated infused therapy. Patients 66 years of age and older in the Surveillance, Epidemiology, and End Results (SEER) program with a CLL diagnosis were matched to their Medicare Part A and Part B claims for long-term follow-up. Treatment patterns, survival after initiation of infused therapy, and both hematologic and hospitalization outcomes were assessed. There were 6433 CLL patients identified, and 2040 received infused therapy. Treated patients were categorized as receiving rituximab monotherapy (16{\%}), rituximab plus chemotherapy (14{\%}), and chemotherapy alone (70{\%}) based on the initial 60 days after infusion. Rituximab plus chemotherapy compared with chemotherapy alone was associated with a 25{\%} lower risk of overall mortality (95{\%} confidence interval, 9{\%}-38{\%}). Restricting to patients age 70 years and older did not change the risk reduction for rituximab plus chemotherapy. Hematologic interventions were more common with rituximab plus chemotherapy compared with chemotherapy alone, but there was no difference in all-cause hospitalizations. These analyses, based on observational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group of older CLL patients are comparable with those demonstrated in younger patients.",
author = "Danese, {Mark D.} and Griffiths, {Robert I.} and Michelle Gleeson and Sacha Satram-Hoang and Kevin Knopf and Mikhael, {Joseph R} and Carolina Reyes",
year = "2011",
month = "3",
day = "31",
doi = "10.1182/blood-2010-08-301929",
language = "English (US)",
volume = "117",
pages = "3505--3513",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

AU - Danese, Mark D.

AU - Griffiths, Robert I.

AU - Gleeson, Michelle

AU - Satram-Hoang, Sacha

AU - Knopf, Kevin

AU - Mikhael, Joseph R

AU - Reyes, Carolina

PY - 2011/3/31

Y1 - 2011/3/31

N2 - The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and to evaluate outcomes in those patients who initiated infused therapy. Patients 66 years of age and older in the Surveillance, Epidemiology, and End Results (SEER) program with a CLL diagnosis were matched to their Medicare Part A and Part B claims for long-term follow-up. Treatment patterns, survival after initiation of infused therapy, and both hematologic and hospitalization outcomes were assessed. There were 6433 CLL patients identified, and 2040 received infused therapy. Treated patients were categorized as receiving rituximab monotherapy (16%), rituximab plus chemotherapy (14%), and chemotherapy alone (70%) based on the initial 60 days after infusion. Rituximab plus chemotherapy compared with chemotherapy alone was associated with a 25% lower risk of overall mortality (95% confidence interval, 9%-38%). Restricting to patients age 70 years and older did not change the risk reduction for rituximab plus chemotherapy. Hematologic interventions were more common with rituximab plus chemotherapy compared with chemotherapy alone, but there was no difference in all-cause hospitalizations. These analyses, based on observational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group of older CLL patients are comparable with those demonstrated in younger patients.

AB - The study goal was to characterize older chronic lymphocytic leukemia (CLL) patients and to evaluate outcomes in those patients who initiated infused therapy. Patients 66 years of age and older in the Surveillance, Epidemiology, and End Results (SEER) program with a CLL diagnosis were matched to their Medicare Part A and Part B claims for long-term follow-up. Treatment patterns, survival after initiation of infused therapy, and both hematologic and hospitalization outcomes were assessed. There were 6433 CLL patients identified, and 2040 received infused therapy. Treated patients were categorized as receiving rituximab monotherapy (16%), rituximab plus chemotherapy (14%), and chemotherapy alone (70%) based on the initial 60 days after infusion. Rituximab plus chemotherapy compared with chemotherapy alone was associated with a 25% lower risk of overall mortality (95% confidence interval, 9%-38%). Restricting to patients age 70 years and older did not change the risk reduction for rituximab plus chemotherapy. Hematologic interventions were more common with rituximab plus chemotherapy compared with chemotherapy alone, but there was no difference in all-cause hospitalizations. These analyses, based on observational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group of older CLL patients are comparable with those demonstrated in younger patients.

UR - http://www.scopus.com/inward/record.url?scp=79953710007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953710007&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-08-301929

DO - 10.1182/blood-2010-08-301929

M3 - Article

VL - 117

SP - 3505

EP - 3513

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -